FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series

2011 ◽  
Vol 26 (1) ◽  
pp. 86-91 ◽  
Author(s):  
Bas B. Koolen ◽  
Erik Vegt ◽  
Emiel J. Th. Rutgers ◽  
Wouter V. Vogel ◽  
Marcel P. M. Stokkel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Case Series ◽  
Breast Cancer Patients ◽  
Sclerotic Bone ◽  
Pet Ct

scholarly journals Usefulness of 18F-fluoride PET/CT in Breast Cancer Patients with Osteosclerotic Bone Metastases

2012 ◽  
Vol 47 (1) ◽  
pp. 27-35 ◽  
Author(s):  
Seok-Ho Yoon ◽  
Ku Sang Kim ◽  
Seok Yun Kang ◽  
Hee-Sung Song ◽  
Kyung Sook Jo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
18F Fluoride

Comparison of 18FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis

2013 ◽  
Vol 22 (2) ◽  
pp. 86-91 ◽  
Author(s):  
Jian Rong ◽  
Siyang Wang ◽  
Qiue Ding ◽  
Miao Yun ◽  
Zhousan Zheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Meta Analysis ◽  
Breast Cancer Patients ◽  
18Fdg Pet ◽  
Pet Ct

EVALUATION OF NEW SCLEROTIC BONE METASTASES IN BREAST CANCER PATIENTS DURING TREATMENT

2000 ◽  
Vol 41 (2) ◽  
pp. 178-182 ◽  
Author(s):  
I. Ciray ◽  
G. Astrom ◽  
I. Andreasson ◽  
T. Edekling ◽  
J. Hansen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Sclerotic Bone

Potential usefulness of OPG, a member of the tumor necrosis factor receptor superfamily, for the early diagnosis of bone metastasis in breast cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22000-e22000
Author(s):  
T. Ibrahim ◽  
E. Sacanna ◽  
L. Mercatali ◽  
E. Flamini ◽  
C. Tison ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Case Series ◽  
Potential Usefulness ◽  
Pcr Analysis ◽  
Breast Cancer Patients ◽  
Healthy Donors ◽  
Disease Free

e22000 Background: Breast cancer is the most frequent tumor in women. About 80% of patients with metastatic disease present bone involvement, in which the OPG/RANKL/RANK system would seem to play an important role. Our aim was to evaluate the potential usefulness of OPG bone marker for the early diagnosis of bone metastases. Methods: The study was carried out on 120 individuals: 30 healthy donors, with a median age of 40 years (21–76) and 90 breast cancer patients, with a median age of 57 years (30–86). Among patients, 49 were disease-free (median age 52 years) and 41 were at first diagnosis of bone metastases (median age 63 years). OPG transcript was determined in peripheral blood samples using quantitative PCR analysis. A receiver operating characteristic (ROC) curve was used to calculate the diagnostic accuracy of the marker. Results: OPG values were not correlated with age in any of the subgroups. The OPG median value was not statistically different in healthy donors (median=1.9; range 0.6–4.7) and disease-free patients (median=1.7; range 0.4–8.9), whereas it was threefold higher than that observed in relapsed patients (median=0.6; range 0.1–5.2; p<0.001), regardless of the number of metastatic sites. The area under the curve (AUC) in disease-free patients was 0.82 for OPG, with 71% sensitivity and 88% specificity, using a cut off ≤ 0.8. In a parallel analysis of 37 patients (14 disease-free and 23 with bone metastases) for whom CEA and CA15.3 information was available, specificity for each marker was 100%, whereas sensitivity was only 61% and 59%, respectively. When these markers were considered in combination with OPG, an increase in sensitivity, albeit not statistically significant, was observed for CEA (83%) and CA15.3 (82%). Conclusions: Our preliminary data show a potential role of the OPG bone turnover marker for the early diagnosis of bone metastases. Results now need to be confirmed in a larger case series. No significant financial relationships to disclose.

scholarly journals Potential of ultra-high-resolution photon-counting CT of bone metastases: initial experiences in breast cancer patients

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
E. Wehrse ◽  
S. Sawall ◽  
L. Klein ◽  
P. Glemser ◽  
S. Delorme ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Resolution ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Therapy Monitoring ◽  
Photon Counting ◽  
Case Series ◽  
Single Photons ◽  
Breast Cancer Patients ◽  
Conventional Ct

AbstractConventional CT scanners use energy-integrating detectors (EIDs). Photon-counting detector (PCD) computed tomography (CT) utilizes a CT detector technology based on smaller detector pixels capable of counting single photons and in addition discriminating their energy. Goal of this study was to explore the potential of higher spatial resolution for imaging of bone metastases. Four female patients with histologically confirmed breast cancer and bone metastases were included between July and October 2019. All patients underwent conventional EID CT scans followed by a high resolution non-contrast experimental PCD CT scan. Ultra-high resolution (UHR) reconstruction kernels were used to reconstruct axial slices with voxel sizes of 0.3 mm × 0.3 mm (inplane) × 1 mm (z-direction). Four radiologists blinded for patient identity assessed the images and compared the quality to conventional CT using a qualitative Likert scale. In this case series, we present images of bone metastases in breast cancer patients using an experimental PCD CT scanner and ultra-high-resolution kernels. A tendency to both a smaller inter-reader variability in the structural assessment of lesion sizes and in the readers’ opinion to an improved visualization of lesion margins and content was observed. In conclusion, while further studies are warranted, PCD CT has a high potential for therapy monitoring in breast cancer.

scholarly journals Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients

2021 ◽  
Author(s):  
Nils Martin Bruckmann ◽  
Julian Kirchner ◽  
Lale Umutlu ◽  
Wolfgang Peter Fendler ◽  
Robert Seifert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Primary Breast Cancer ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Initial Staging

Abstract Objectives To compare the diagnostic performance of [18F]FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Material and methods A cohort of 154 therapy-naive patients with newly diagnosed, histopathologically proven breast cancer was enrolled in this study prospectively. All patients underwent a whole-body [18F]FDG PET/MRI, computed tomography (CT) scan, and a bone scintigraphy prior to therapy. All datasets were evaluated regarding the presence of bone metastases. McNemar χ2 test was performed to compare sensitivity and specificity between the modalities. Results Forty-one bone metastases were present in 7/154 patients (4.5%). Both [18F]FDG PET/MRI and MRI alone were able to detect all of the patients with histopathologically proven bone metastases (sensitivity 100%; specificity 100%) and did not miss any of the 41 malignant lesions (sensitivity 100%). CT detected 5/7 patients (sensitivity 71.4%; specificity 98.6%) and 23/41 lesions (sensitivity 56.1%). Bone scintigraphy detected only 2/7 patients (sensitivity 28.6%) and 15/41 lesions (sensitivity 36.6%). Furthermore, CT and scintigraphy led to false-positive findings of bone metastases in 2 patients and in 1 patient, respectively. The sensitivity of PET/MRI and MRI alone was significantly better compared with CT (p < 0.01, difference 43.9%) and bone scintigraphy (p < 0.01, difference 63.4%). Conclusion [18F]FDG PET/MRI and MRI are significantly better than CT or bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. Both CT and bone scintigraphy show a substantially limited sensitivity in detection of bone metastases. Key Points • [18F]FDG PET/MRI and MRI alone are significantly superior to CT and bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. • Radiation-free whole-body MRI might serve as modality of choice in detection of bone metastases in breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document